ERCC1 and Clinical Resistance to Platinum-Based Therapy

This publication has 21 references indexed in Scilit:

• ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer
  Clinical Cancer Research, 2005
• Nucleotide Excision Repair in E. Coli and Man
  Advances in Protein Chemistry, 2004
• Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines
  Cancer Gene Therapy, 2002
• An ERCC1 splicing variant involving the 5′-UTR of the mRNA may have a transcriptional modulatory function
  Oncogene, 2001
• A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues
  Mutation Research/Mutation Research Genomics, 1997
• Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification
  Cancer Letters, 1996
• Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
  Journal of Clinical Investigation, 1994
• Expression of excision repair genes in non-malignant bone marrow from cancer patients
  Mutation Research/DNA Repair, 1993
• ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer Patients
  JNCI Journal of the National Cancer Institute, 1992
• Molecular characterization of the human excision repair gene : cDNA cloning and amino acid homology with the yeast DNA repair gene
  Cell, 1986